Blog
RSS FeedPosted by Michael Wonder on 22 Sep 2022
13 million Novavax doses due to expire as Australians stick to mRNA boosters
21 September 2022 - Novavax COVID vaccines procured by the federal government in the hopes of convincing hesitant Australians to ...
Posted by Michael Wonder on 31 Aug 2022
Pharmaceutical Benefits Scheme supplied medications
30 August 2022 - Key findings about health and population characteristics from the National Health Survey (NHS) and the Pharmaceutical Benefits ...
Posted by Michael Wonder on 03 Aug 2022
U.S. prescription drug market lacks certain competitive features: case of biosimilars
3 August 2022 - In a legal ruling reported yesterday, a 7th Circuit Court Federal Judge, Frank Easterbrook, affirmed dismissal of ...
Posted by Michael Wonder on 13 Jul 2022
Biosimilar uptake accelerates in US—and so do the savings
13 July 2022 - Amgen's early view said health care savings from the use of these biologic therapies climbed to ...
Posted by Michael Wonder on 11 Jul 2022
Drug Utilisation SubCommittee outcome statement
8 July 2022 - The outcome statement from the June 2022 DUSC meeting is now available. ...
Posted by Michael Wonder on 03 Jul 2022
NHS saves 1.2 billion pounds on medicines over three years
1 July 2022 - The NHS has saved taxpayers £1.2 billion in just three years, while securing cutting-edge treatments for ...
Posted by Michael Wonder on 21 May 2022
People dying of COVID while life-saving drugs go unused, doctors say
21 May 2022 - Top doctors have warned that vulnerable patients who test positive to COVID-19 are missing out on ...
Posted by Michael Wonder on 19 Apr 2022
Prioritising reference products over biosimilars led to millions of missed savings for Part D
20 April 2022 - Medicare Part D plans missed out on between $84 million and $143 million in savings by ...
Posted by Michael Wonder on 06 Apr 2022
Some hoped FDA approval of Pfizer's COVID vaccine would convince unvaccinated Americans. It didn't, study finds.
6 April 2022 - After the Food and Drug Administration approved Pfizer-BioNTech’s COVID-19 vaccine in August, public health experts were ...
Posted by Michael Wonder on 25 Mar 2022
DUSC utilisation analysis public release documents
25 March 2022 - The utilisation analysis public release documents from the October 2021 DUSC meeting are now available. ...
Posted by Michael Wonder on 14 Feb 2022
Medscape awarded contract from FDA to develop educational programming focused on biosimilars
14 February 2022 - Medscape Education has been awarded a contract from the U.S. FDA for the development of an ...
Posted by Michael Wonder on 16 Nov 2021
Are we measuring what matters most on uptake to medicines in England?
16 November 2021 - VPAS is a voluntary agreement between the UK government and the Association of the British Pharmaceutical ...
Posted by Michael Wonder on 05 Nov 2021
Drug Utilisation Sub-Committee outcome statement
5 November 2021 - The Outcome Statement from the October 2021 Drug Utilisation SubCommittee meeting is now available. ...
Posted by Michael Wonder on 24 Oct 2021
Patient and payer incentives to use patented brand name drugs vs authorised generic drugs in Medicare Part D
18 October 2021 - This cross-sectional study of Medicare formulary and pricing data for quarter 3 of 2020 found that most ...
Posted by Michael Wonder on 24 Oct 2021
Real world use of and spending on new oral targeted cancer drugs in the US (2011-2018)
18 October 2021 - In this cross-sectional study among 37 348 patients who received 1 or more of 44 new oral targeted ...